Table 6.
Male | Female | |||
---|---|---|---|---|
Control (n = 10) | Omega-3 (n = 10) | Control (n = 10) | Omega-3 (n = 10) | |
RETROPERITONEAL | ||||
SREBP-1c mRNA (×1000) | 0.9 ± 0.02 | 1.4 ± 0.3 | 1.7 ± 0.4 | 1.8 ± 0.5 |
PPARγ mRNA | 0.0143 ± 0.003 | 0.0161 ± 0.003 | 0.0141 ± 0.003 | 0.0136 ± 0.003 |
FAS mRNA | 0.131 ± 0.058 | 0.152 ± 0.039 | 0.567 ± 0.085# | 0.316 ± 0.084#† |
G3PDH mRNA | 0.099 ± 0.03 | 0.253 ± 0.08 | 0.343 ± 0.056 | 0.233 ± 0.065 |
Leptin mRNA | 0.0153 ± 0.006 | 0.0122 ± 0.005 | 0.0071 ± 0.002 | 0.0068 ± 0.002 |
SUBCUTANEOUS | ||||
SREBP-1c mRNA | 0.0087 ± 0.0030 | 0.0075 ± 0.0006 | 0.0087 ± 0.003 | 0.0130 ± 0.005 |
PPARγ mRNA (×1000) | 0.82 ± 0.03 | 0.67 ± 0.02 | 1.7 ± 0.7 | 0.7 ± 0.3 |
FAS mRNA | 0.251 ± 0.060 | 0.256 ± 0.130 | 0.353 ± 0.170 | 0.104 ± 0.047 |
G3PDH mRNA | 0.220 ± 0.11 | 0.221 ± 0.089 | 0.363 ± 0.180 | 0.105 ± 0.046 |
Leptin mRNA | 0.0028 ± 0.001 | 0.0024 ± 0.002 | 0.0024 ± 0.001 | 0.0021 ± 0.001 |
All values expressed as mean ± SEM. The effect of Omega-3 treatment and sex was determined using a two-way ANOVA. #denotes P < 0.05 compared to male offspring; †denotes P = 0.06 compared to Control females.